KRYS Krystal Biotech Inc

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 3, 2025, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: .

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

CONTACT

Investors and Media:                                                             

Stéphane Paquette, PhD

Krystal Biotech



EN
21/10/2025

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan He...

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of growth of its rare diseas...

January 11, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Positive Interim Clinical Update from KB407 ...

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% Registrational repeat dosing CORAL-3 study design submitted to FDA in late December; anticipat...

January 8, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Announce Interim Clinical Update from Highest Dose ...

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company’s multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cyst...

January 7, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Confe...

Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be po...

January 5, 2026 1 EN
Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 1 director

A director at Krystal Biotech Inc sold 25,000 shares at 220.150USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

KRYS KRYSTAL BIOTECH INC
12/08/25 December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch